Navigation Links
Technolas 217z Zyoptix System

ProductsTechnolas 217z Zyoptix System
Company Bausch & Lomb Storz
Item Technolas 217z Zyoptix System
Features 
  • Newest generation flying spot/scanning technology utilizing a 1mm and 2mm truncated Gaussian beam for fast treatment times and a smooth corneal surface.
  • Active scanner feedback mechanism provides quality control during the procedure by monitoring the accuracy of each pulse placement.
  • Strategic space design allows maximum instrument control and flexibility for surgeons and provides excellent comfort for patients.
  • Efficient data transfer from the Zyoptix Diagnostic Workstation provides the surgeon with optimum surgical management.
    • Description Using flying spot technology the Technolas 217z Zyoptix System, the world's leading wavefront-guided laser for personalized vision correction, allows surgeons in the United States to treat myopia up to -7.00 Diopters and astigmatism up to -3.00 Diopters. The Technolas 217z Zyoptix System combines both a 2mm and 1mm truncated Gaussian beam, with an active eye tracker for fast treatment times and a smooth stromal bed. Providing outstanding clinical outcomes in U.S. FDA clinical trials, the Technolas 217z Zyoptix System features a proven custom ablation algorithm with over 100,000 procedures performed worldwide.
    Info Bausch & Lomb Storz
    Customer Service: (585) 338-6000

    Related medicine products :

    1. Zyoptix Diagnostic Workstation
    2. Silicone Oil Cannula System - 20 Gauge
    3. Silicone Oil Cannula System - 19 Gauge
    4. SuperVu Galilean System
    5. KOWA nonmyd 7 / VK-2 Digital Imaging System
    6. KOWA nonmyd a-D / VK-2 Digital Imaging System
    7. Refraction System RT-2100
    8. Odyssey Phacoemulsification System
    9. SIStem Phacoemulsification System
    10. Precisionist Phacoemulsification System
    11. Photon Laser Phacoemulsification System
    Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
    Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
    Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
    OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
    Medicine Products:
    (Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
    (Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
    (Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
    (Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
    Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
    ...ofi-Aventis, one of the world's leading pharmaceut... Taxotere (docetaxel) improves survival in patient... clinical trial named TAX 327 compared Taxotere pl...one) plus prednisone. The study included a little ...
    ...nagers who use mobile phones for many hours a day ...ay develop psychological disorders, says a study t...s. // Francisca Lopez Torrecillas, a lecturer at t...chological assessment and treatment of the Univers...
    ...ian belief and knowledge are great healers and 140...rently in Delhi to study this value system. // "Th...tal role in dealing with mental health issues and ...re about it," said Patrick Bantman, a psychiatrist...
    ...en aiming to shed after-pregnancy pounds should ad...cording to a new study by Harvard researchers. // ...isk for weight gain in women,” said lead author Em...n that early postpartum period — such as diet, tel...
    Other Medicine News:Health News:Mobile Phone Addiction may Cause Psychological Problems 2Health News:Simple Solutions to Postpartum Weight Retention 2
    (Date:10/13/2008)... to Have Higher Sensitivity and Specificity, than...was the preferred test in all phas... 13 /- AT First Diagnostic LLC an,eme...ic test kits, today,announced that a recent evalua...f Research of the FirstVue(TM) HBSAG Test, was rel...
    (Date:10/13/2008)...- Facet Solutions, Inc. today,announc...nts from its US,IDE Pilot Study. The results show ... scores, and an 80% reduction in Visual Analog Sco...resident & CEO for Facet Solutions,added, "We are... far not,only demonstrate significant pain relief ...
    (Date:10/12/2008)...N, Oct. 12 /- Boston,Scient...ults from an analysis,of nearly 7,500 patients fro...esigned to confirm the performance of the TAXUS(R)...stem in real-world practice. The,two-year pooled A...nical,restenosis in patients with diabetes as effe...
    (Date:10/10/2008)...is Treatment with Kogenate FS Reduces the,Risk of ...No Pre-Existing,Joint Damage, BERKELEY, Calif., O...ced today that the U.S. Food and Drug Administrati...enate(R) FS Antihemophilic Factor,(Recombinant) to... risk of,joint damage in patients aged 0-16 years ...
    Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Shingles Pain Treatment Will Benefit More Patients 2872 1Shingles Pain Treatment Will Benefit More Patients 2872 2Shingles Pain Treatment Will Benefit More Patients 2872 3Shingles Pain Treatment Will Benefit More Patients 2872 4Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 1Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 1Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 21New Health Knowledge Base and Semantic Search Engine Announced 25637 1New Health Knowledge Base and Semantic Search Engine Announced 25637 2
    ...d Insurance Coverage Varies,Greatly for Different ... 2007-- Most U.S. adults support,approving the use...act people,s quality of life, including birth cont...reat erectile,dysfunction and improve memory and t...ieve these types of treatments should be covered,b...
    ...y 1, 2007 - Progenics,Pharmaceuticals, Inc. (NASDA... first clinical trial of its investigational drug,...mmunodeficiency,virus (HIV), the causative agent o... of PRO 140 achieved an average maximum,decrease o...,log10), with individual reductions ranging up to ...
    Other Medicine Technology:Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 2Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 5Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 6Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 7